Deal-Making
thumbnail
Deal MakingIncyte gains Monjuvi as Novartis acquires MorphoSysIncyte gains Monjuvi as Novartis acquires MorphoSys
MorphoSys has offloaded cancer monoclonal antibody (mAb) monjuvi (tafasitamab) to Incyte Corporation ahead of its $2.9 billion acquisition by Novartis.